Thus, the combined assessment of SATB2 protein expression and TP53 gene mutation status is crucial for differentiating PHO from other hepatic malignancies, including hepatic cystadenocarcinoma, cholangiocarcinoma and carcinosarcoma. This evidence concerns the gene TP53 and cholangiocarcinoma.